Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Otorhinolaryngology
Reference21 articles.
1. Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, et al (2014) Cancer incidence in five continents volume I to X. IARC Cancer Base No. 12. IARC Press (
http://gco.iarc.fr
). Also at
http://seer.cancer.gov/statfacts/html/oralcav.html
. Accessed 1 Feb 2017
2. Pignon JP, Le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14
3. Hoek J, Bloemendal KM, van der Velden LA, van Diessen JN, van Werkhoven E, Klop WM et al (2016) Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas. Cancers (Basel) 8:21
4. Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P et al (2016) Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck 38:2151–2158
5. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35